Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.53 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 5/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.50 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685198 | 0.95 | TAS2R14 (0.53) | TAS2R14VCAM1GRIA1GRIA2GRIA3 | |
| SCHEMBL3682051 | 0.84 | MAPT (0.62) | VCAM1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3692380 | 0.82 | VCAM1 (0.54) | VCAM1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3686541 | 0.81 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3683066 | 0.79 | MAPT (0.52) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3687754 | 0.79 | MAPT (0.62) | VCAM1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3683417 | 0.78 | ALDH1A1 (0.51) | VCAM1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3682827 | 0.78 | GRIA1 (0.75) | TAS2R14VCAM1GRIA1GRIA2GRIA3 | |
| SCHEMBL9746859 | 0.77 | GRIA1 (0.47) | VCAM1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3680520 | 0.73 | GRIA1 (0.47) | VCAM1GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8603980-B2 | Glutamate receptor antagonists and methods of use | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-12-10 | — | — | US | disclosed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| EP-0511152-A2 | Quinoxaline compounds, their preparation and use | NOVO NORDISK A/S (DK) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | TAS2R14 1868/4885VCAM1 222/4885GRIA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.